GLP-1 receptor agonists, a class of drugs originally developed for type 2 diabetes and obesity that have recently transformed metabolic medicine, target the downstream consequences of that hormonal withdrawal: dysregulated energy metabolism, inflammation, and shifts in body composition
The only RCT to date exploring GLP-1 analogues for HO was a 36-week study conducted in 2021 including 35 participants completing the study
What might be the optimal injection timing during early titration phases may not be the same consideration at a maintenance dose where side effects are minimal
Semaglutide is available in a compounded semaglutide formulation and as the active ingredient in brand-name medications Wegovy, Rybelsus, and Ozempic
We accept insurance plans from major providers like UnitedHealthcare and Medicare, ensuring you have access to the support you need
Timing Matters Align your eating window with your bodys natural rhythms